Target intelligence / Profile preview

Prostaglandin F2 receptor negative regulator (PTGFRN)

Target: PTGFRN
Molecular classification: Receptor-associated accessory protein, Transmembrane protein, Tetraspanin-associated protein, CD (cluster of differentiation) family

Overview

Prostaglandin F2 receptor negative regulator (PTGFRN, CD315) is a transmembrane accessory protein that inhibits prostaglandin F2α receptor activity mainly by reducing the receptor's density on the cell surface, thereby modulating prostaglandin signaling in pathways relevant to inflammation, immune response, reproduction, cardiovascular biology, and cancer. PTGFRN is a member of the CD protein family and interacts with tetraspanins (CD9, CD81), integrins, and cadherins, facilitating cell adhesion, migration, and cellular communication[1][3][5][7]. PTGFRN is implicated in the progression and metastasis of several cancers, as well as other disorders linked to prostaglandin and cell surface signaling—making it a candidate for research and therapeutic intervention[2][5].

Other names: PTGFRNCD315FPRPEWI-FCD9P-1SMAP-6Glu-Trp-Ile EWI motif-containing protein FProstaglandin F2 receptor inhibitorProstaglandin F2-alpha receptor regulatory proteinProstaglandin F2-alpha receptor-associated proteinCD9 partner 1

Mechanism of action

Inhibition or modulation of PTGFRN alters prostaglandin signaling by decreasing FP receptor density, thereby reducing cell proliferation, migration, and metastasis—especially in cancer cell lines. Disrupting PTGFRN interaction with tetraspanin, integrin β1, or cadherin pathways can interfere with cellular adhesion and migration

Biological functions

Regulation of prostaglandin F2α signaling (by affecting FP receptor density on cell surface)Cell adhesion and migration (via interactions with tetraspanins and integrins)Immune modulationPromotion of metastatic phenotype in cancerAutophagy regulationMyoblast fusion (skeletal muscle regeneration)

Disease associations

Cancer (correlated with metastatic features and tumor progression)Inflammatory diseasesCardiovascular disordersReproductive disordersAutoimmune diseases

Safety considerations

Modulation of PTGFRN could affect immune responses, cell adhesion, and multiple physiological processes, posing risks such as impaired tissue regeneration, altered inflammatory or immune activity, and unknown cardiovascular or reproductive side effects due to broad tissue distribution and biological roles

Interacting drugs

No approved drugs directly targeting PTGFRN are listed in current clinical use. Research antibodies and experimental inhibitors exist for laboratory use

Biomarkers

PTGFRN protein and gene expression levels may serve as research biomarkers for cancer metastasis and possibly for patient selection in experimental therapies targeting prostaglandin signaling and cell migration

Beyond the preview

Go deeper on Prostaglandin F2 receptor negative regulator (PTGFRN).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Explore the programs pursuing this target and their development progress.

Drug candidates
Developers
Development stage

Clinical trials

Follow the clinical studies evaluating therapies directed at this target.

Trial design
Status
Readouts

Competitive landscape

Compare approaches across drug candidates, modalities, and indications.

Programs
Modalities
Indications

Literature & evidence

Investigate the research and source evidence behind target biology and development.

Publications
Sources
Analysis

Patents

Explore patent activity around therapies and technologies addressing this target.

Patents
Assignees
Technologies

Research & analysis

Connect target biology, drug development, and emerging evidence in your research.

Biology
Development news
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Prostaglandin F2 receptor negative regulator (PTGFRN).

Explore the full profile